[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"solid-organ-transplantation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:solid-organ-transplantation":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,51,82,115,145,188,212],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100641346","liposomal-amphotericin-b-for-invasive-fungal-disease-in-solid-organ-transplant-recipients-100641346",false,"NCT07656493","Liposomal Amphotericin B for Invasive Fungal Disease in Solid Organ Transplant Recipients","A Real-World Observational Study of the Effectiveness, Safety, and Therapeutic Drug Monitoring of Liposomal Amphotericin B in Solid Organ Transplant Recipients With Invasive Fungal Disease","LAMB-SOT","Inclusion Criteria:\n\n* Age 18 to 75 years.\n* Recipient of a solid organ transplant.\n* Diagnosis of invasive fungal disease (IFD) according to EORTC\u002FMSGERC criteria.\n* Receiving liposomal amphotericin B therapy as part of routine clinical care.\n* Provision of informed consent for prospective participants.\n\nExclusion Criteria:\n\n* Known hypersensitivity to amphotericin B formulations.\n* Severe hepatic dysfunction (ALT or AST \\>5× upper limit of normal, or total bilirubin \\>2× upper limit of normal).\n* Severe renal dysfunction requiring permanent discontinuation of antifungal therapy at baseline.\n* Pregnancy or breastfeeding.\n* Participation judged inappropriate by the investigator.","ALL","18 Years",{"count":20,"type":21},120,"ESTIMATED","OBSERVATIONAL","This real-world observational study aims to evaluate the effectiveness, safety, and therapeutic drug monitoring (TDM) of liposomal amphotericin B (L-AmB) in solid organ transplant recipients with invasive fungal disease (IFD). IFD is a major cause of morbidity and mortality in transplant recipients because of long-term immunosuppressive therapy and increased susceptibility to opportunistic fungal infections.\n\nThis is a single-center ambispective cohort study conducted at Sichuan Provincial People's Hospital. The study includes a prospective cohort of solid organ transplant recipients receiving L-AmB therapy and a historical control cohort treated with alternative systemic antifungal regimens. Clinical management and treatment decisions will be determined by treating physicians according to routine clinical practice, and no study-specific intervention will be introduced.\n\nThe study will collect information on demographic characteristics, transplant type, immunosuppressive regimens, fungal pathogens, infection sites, antifungal treatment strategies, laboratory findings, and clinical outcomes. Particular attention will be given to renal safety, electrolyte abnormalities, and therapeutic drug monitoring of liposomal amphotericin B. Plasma concentrations of L-AmB, treatment modifications, temporary treatment discontinuation, and concentration-related safety and effectiveness outcomes will be recorded during antifungal therapy.\n\nThe primary outcomes are the 28-day clinical response rate and 84-day all-cause mortality. Secondary outcomes include mycological clearance, acute kidney injury, electrolyte abnormalities, breakthrough fungal infection, treatment discontinuation due to adverse events, liposomal amphotericin B plasma concentrations, and the associations between L-AmB exposure and clinical outcomes or treatment-related toxicities.\n\nThe study is expected to provide real-world evidence regarding the effectiveness, safety, and pharmacokinetic characteristics of L-AmB in transplant recipients, support optimization of antifungal treatment strategies, and inform individualized dosing and monitoring approaches in this high-risk population.",[25,26,27],"Invasive Fungal Infection","Solid Organ Transplantation","Opportunistic Infections",[29,26,30,31,32,33,34,35,36,37],"Liposomal Amphotericin B","Invasive Fungal Disease","Antifungal Therapy","Tacrolimus","Cyclosporine","Therapeutic Drug Monitoring","Drug-Drug Interaction","Real-World Study","Transplant Infection","NOT_YET_RECRUITING","2026-06-19",{"date":41,"type":42},"2026-06-24","ACTUAL",{"date":44,"type":21},"2026-07-01",{"date":46,"type":21},"2028-06-30",{"name":48,"class":49},"Sichuan Provincial People's Hospital","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":50},"100637848","evaluate-the-performance-of-the-dexcom-g7-continuous-glucose-monitoring-cgm-system-in-critically-ill-patients-undergoing-major-abdominal-surgery-and-solid-organ-transplantation-which-require-blood-glucose-monitoring-for-intensive-insulin-therapy-100637848","NCT07611721","Evaluate the Performance of the Dexcom G7 Continuous Glucose Monitoring (CGM) System in Critically Ill Patients Undergoing Major Abdominal Surgery and Solid Organ Transplantation Which Require Blood Glucose Monitoring for Intensive Insulin Therapy.","Determining the Reliability and Accuracy of the Dexcom G7 Continuous Glucose Monitoring System in the ICU","DREAM-ICU","Inclusion Criteria:\n\n* Age 18 years or over\n* Intensive care unit admission\n* Requiring blood glucose monitoring for insulin therapy\n\nExclusion Criteria:\n\n* High-dose ascorbic acid or acetaminophen \\> 4g\u002Fday\n* Physical or mental health condition precluding continuous wear of the continuous glucose monitor, as judged by the physician",{"count":60,"type":21},62,"INTERVENTIONAL",[63],"NA","Main objective:\n\nThe goal is to to determine the accuracy of Dexcom G7 Continuous glucose monitor system in critically ill patients, undergoing major abdominal surgery and solid organ transplantation, in the intensive care unit.\n\nOn admission to the intensive care unit or at the end of surgery, two Dexcom G7 sensors are placed in the infraclavicular position.\n\nSensor number 1 will be blinded and will only be active when paired with the receiver, without the ability to monitor glucose levels.\n\nSensor number 2 is used for continuous glucose monitoring and can be used to adjust the insulin dose.\n\nPatients will wear the continuous glucose monitoring sensor for a maximum of 10 days, including the time spent in the intensive care unit and the immediate care unit. The study will not interfere with any usual care clinical workflows.\n\nCalibration is only performed on an unblinded sensor. The reference method for calibration is the glucose from the blood glucose meter.\n\nCalibrate on the first day of monitoring: 4 times a day after approximately 6 hours, or if the blood glucose reading from the blood glucose meter is not within the estimated error range of the continuous glucose monitor (difference greater than 1,5mmol\u002FL).\n\nCalibration on days 2 and 3 of monitoring: once in the morning, or when the meter's glucose reading is not within the estimated error range of the continuous glucose monitoring (difference greater than 1,5mmol\u002FL) On subsequent days when the blood glucose meter reading is not within the estimated error range of continuous glucose monitoring (difference greater than 1,5mmol\u002FL).\n\nHypothesis:\n\n* Ho: No difference in mean absolute relative difference (MARD) between calibrated and non-calibrated sensors.\n* Ha: Calibrated sensors have lower mean absolute relative difference (δ = 4%, SD = 5%).\n\nFurther objectives:\n\nTo evaluate further aspects regarding the Dexcom G7 continuous glucose monitor system's performance in the intensive care unit (ICU), particularly in terms of sensitivity and specificity to detect hypo- and hyperglycaemic events, data availability, device deficiencies and safety.\n\nTo identify predictive factors of the accuracy of the Dexcom G7 continuous glucose monitor system in critically ill patients in the ICU.",[66,67,68,26,69,70],"CGM","Intensive Care (ICU)","Liver Transplant Surgery","Major Abdominal Surgeries","Diabetes (Insulin-requiring, Type 1 or Type 2)","RECRUITING","2026-05-20",{"date":74,"type":42},"2026-05-28",{"date":76,"type":42},"2026-01-14",{"date":78,"type":21},"2027-04",{"name":80,"class":81},"Institute for Clinical and Experimental Medicine","OTHER_GOV",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":92,"conditions":93,"keywords":100,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":50},"100463707","molecular-prediction-of-development-progression-or-complications-of-kidney-immune-or-transplantation-related-diseases-100463707","NCT05318196","Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases","NEPHROGENE2","Inclusion Criteria:\n\n* Patients (\\> 18 year of age) with kidney disease or at risk to develop a kidney disease,\n* Patients followed by a practitioner of the Department of Nephrology and Organ Transplantations of the University Hospital of Toulouse (France)\n\nExclusion Criteria:\n\n* consent deny\n* inability of the patient or its family to give consent.","99 Years",{"count":91,"type":21},5000,"Managing patients with renal failure requires an understanding of the molecular mechanisms that lead to its occurrence (i.e. upstream of the disease), its worsening and its persistence (i.e. downstream), while also specifying the risk of worsening renal failure (risk stratification, intolerance to the treatment or complications (infectious, metabolic, cardiovascular, cancer…). Nephrogene 2.0 aims to study these different components of kidney, immune and solid organ transplantation (SOT)-related diseases.",[94,95,96,97,98,99],"Acute Kidney Injury","Chronic Kidney Diseases","Solid-organ Transplantation","Cancer","Metabolic Disease","Immune Diseases",[101,102,103,104,105],"risk stratification","solid-organ transplantation","cancer","Chronic kidney disease","Acute kidney injury","2026-03-16",{"date":108,"type":42},"2026-03-19",{"date":110,"type":42},"2022-09-05",{"date":112,"type":21},"2032-09-01",{"name":114,"class":49},"University Hospital, Toulouse",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":4},"100623008","integrating-vaccination-into-hospital-care-pathways-for-vulnerable-patients-100623008","NCT07391046","Integrating Vaccination Into Hospital Care Pathways for Vulnerable Patients","Integrating Vaccination Into Hospital Care Pathways for Vulnerable Patients: A Scalable and Sustainable Model","AMBU-VAX","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Presence of at least one chronic or immunocompromising condition eligible for vaccination according to national guidelines\n* Written informed consent provided\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Conditions not included among the predefined eligibility criteria",{"count":124,"type":21},1500,"AMBU-VAX is a prospective, single-center observational study designed to develop and implement an organizational model for delivering recommended vaccinations within a hospital setting.\n\nThe study targets adult and elderly patients with chronic diseases or immunocompromising conditions who are eligible for vaccination according to national immunization guidelines. Vaccination is actively proposed during outpatient visits, hospital admissions, or at discharge and, when accepted, administered within the hospital or coordinated with local public health vaccination services.\n\nThe study aims to evaluate the feasibility, uptake, and completion of hospital-based vaccination pathways and to support integration between hospital and territorial prevention services for vulnerable populations.",[127,128,129,130,26,131,97,132,133,134,135],"Chronic Disease","Immunocompromised","HIV Infection","Chronic Kidney Disease","Hematopoietic Stem Cell Transplantation","Autoimmune Diseases","Inflammatory Bowel Disease","Asplenia","Frailty","2026-01-29",{"date":138,"type":42},"2026-02-05",{"date":140,"type":21},"2026-02",{"date":142,"type":21},"2027-02",{"name":144,"class":49},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":152,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":155,"conditions":156,"keywords":169,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":50},"100615334","long-term-follow-up-of-the-offspring-born-to-mothers-with-a-solid-organ-transplant-transplantlines-next-generation-100615334","NCT07291258","Long-term Follow-up of the Offspring Born to Mothers With a Solid Organ Transplant, Transplantlines Next Generation","Long-term Follow-up of the Offspring Born to Mothers With a Solid Organ Transplant","Inclusion Criteria:\n\n* Mother with a KTx, LiTx, PTx (including pancreas islet transplantation), HTx or LuTx before pregnancy (including mothers with multiple transplantation types)\n* Age ≥16 years for offspring born to mother with a KTx or LiTx\n\nExclusion Criteria:\n\n* No informed consent\n* Non Dutch or English speaking",true,{"count":154,"type":21},200,"Background Pregnancy after all types of solid organ transplantation (SOT) is possible, although these have higher risk of pregnancy complications for mother and child, such as preeclampsia and preterm birth. Thus, the development of the unborn child seems to be affected by the transplant and its consequences such as the immunosuppressive medication use. Worldwide data regarding follow-up after birth is scarce. The very limited existing data existing only in young children are reassuring. However, the investigators hypothesize that there are health risks for the children. Given the side effects of the immunosuppressive medication on patients and limited knowledge from animal studies, the investigators particularly expect cardiovascular effects such as hypertension and kidney damage. These develop over a long time-period and lead late to symptoms.\n\nAims Aim of this study is to gain more insight into the overall health of offspring born after SOT. Primary aim is to assess the cardiovascular health and the presence of kidney disease, and compare these with reference values from the general population or birth cohorts. Secondary aims are the immunological status including the microbiome of the child given the maternal immunosuppressive medication use, and the overall development of the offspring, including qualitative research regarding the quality of life. Third aim is to assess if there are differences in health between offspring born to mothers with a kidney, liver, pancreas (including pancreas islet), heart and lung transplantation (KTx, LiTx, PTx, HTx, LuTx resp.). The investigators also want to establish a biobank for later follow-up research.\n\nStudy design This will be a cross-sectional monocenter cohort study. All offspring ≥16 years of age born after KTx or LiTx and all offspring born at any age after PTx, HTx and LuTx in the Netherlands will be eligible for inclusion. The investigators estimate that there will be about 150(-220) participants. Before the study visit, participants will be asked to complete a questionnaire. Participants will be invited for a one-time study visit consisting of physical tests (including ultrasound of the kidneys and a 24-hour ambulatory blood pressure measurement) and biological sample (urine, blood and feces) collection, including sample collection for biobanking. Information about the growth and development of the offspring and, if present, diseases and medication use will be collected from the medical files of the general practitioner and pharmacy (LSP) and from data from the youth healthcare check-ups. As a control group pseudoanonymized data from the Lifelines cohort will be used.\n\nDeliverables To the best of our knowledge, this will be the first study worldwide that will gather and analyze detailed information about the cardiovascular, kidney and immunological health at a later age (≥16 years) in the offspring born to mothers after KTx, LiTx, PTx, HTx and LuTx. This information will be important for the preconceptional counseling of families with a pregnancy wish after transplantation and thereby contribute to the health of women with a SOT. Next to that, find adverse effects of the pregnancy after transplantation on the offspring are found, the investigators expect there will be modifiable factors and\u002For early screening\u002Finterventions that can reduce these risks and thereby contribute to the health of the offspring.",[26,157,158,159,160,161,162,163,164,165,166,167,168],"Pregnancy","Long-term Follow-up","Kidney Transplant","Liver Transplant","Pancreas Transplant","Heart Transplantation","Lung Transplantation","Offspring, Adult","Children","Cardiovascular Abnormalities","Kidney Disease","Quality of Life",[170,157,171,172,173,174,175,176,177,178],"Solid organ transplantation","Offspring","Long-term follow-up","kidney transplantation","liver transplantation","pancreas transplantation","pancreas islet transplantation","Heart transplantation","lung transplantation","2025-12-04",{"date":181,"type":42},"2025-12-18",{"date":183,"type":42},"2025-10-15",{"date":185,"type":21},"2028-06",{"name":187,"class":49},"University Medical Center Groningen",{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":197,"conditions":198,"keywords":200,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":50},"100145373","biomarkers-in-transplant-recipients-to-improve-outcomes-100145373","NCT01163578","Biomarkers in Transplant Recipients to Improve Outcomes","Study of Biomarkers in Solid Organ and Bone Marrow Transplant Recipients to Better Treat Rejection","Inclusion Criteria:\n\n* Recipients of abdominal, thoracic and bone marrow allografts that are receiving inpatient and outpatient follow-up with routine laboratory tests at the University of Pittsburgh Medical Center.\n* All Ages\n* Subject or parents are able to read and understand the informed consent\n\nExclusion Criteria:\n\n* Subjects and\u002For their parents who are unable to read and understand informed consent.",{"count":196,"type":21},1200,"The objective of this study is to evaluate whether certain proteins, expressed in biological tissues can indict a better understanding of the effect of drugs that are used to treat rejection, and of processes leading to rejection and rejection-free outcomes.",[26,199],"Bone Marrow Transplantation",[201,202],"Transplantation","Rejection","2025-09-05",{"date":205,"type":42},"2025-09-09",{"date":207,"type":4},"2005-03",{"date":209,"type":21},"2030-03",{"name":211,"class":49},"University of Pittsburgh",{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":216,"acronym":217,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":221,"conditions":222,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":232},"100575596","biomarkers-and-inflammation-in-solid-organ-transplantation-relationship-with-short--and-long-term-outcomes-100575596","NCT06774339","Biomarkers and Inflammation in Solid Organ Transplantation: Relationship With Short- and Long-Term Outcomes","Bio-Trap","Inclusion Criteria:\n\n* Adult patients (≥ 18 years old at the time of enrollment) who have undergone at least one of the following: Liver transplant, Kidney transplant, Heart transplant, Lung transplant during the study period.\n* Informed consent acquisition.\n\nExclusion Criteria:\n\n* none",{"count":220,"type":21},250,"This is a prospective, tissue-based, low-risk, non-pharmacological study that will include adult patients undergoing solid organ transplantation (heart, liver, lung, kidney) followed at the following Units of the IRCCS Azienda Ospedaliero-Universitaria di Bologna (IRCCS AOUBO):\n\n* Heart Failure and Transplants (heart-lung)\n* Internal Medicine for the Treatment of Severe Organ Failures (liver)\n* Nephrology, Dialysis, and Transplantation (kidney).",[26],"2025-01-09",{"date":225,"type":42},"2025-01-14",{"date":227,"type":42},"2024-10-10",{"date":229,"type":21},"2031-12",{"name":231,"class":49},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",3]